Trial-to-trial variability in survival by age group
| Trial . | Group . | Median survival, wk (95% CI) . | ||
|---|---|---|---|---|
| Overall . | Age < 60 y . | Age ≥ 60 y . | ||
| IA | IA | 77 (56-132) | 169 (96 to —) | 47 (32-69) |
| n = 84 | n = 54 | n = 30 | ||
| IA + G-CSF (G) | IA | 86 (58-123) | 123 (86-182) | 36 (17-94) |
| n = 144 | n = 83 | n = 61 | ||
| IA + G + ATRA | IA | 83 (41 to —) | 81 (34 to —) | 83 (52 to —) |
| n = 25 | n = 20 | n = 5 | ||
| IA ± lisofylline | IA | 53 (44-88) | 61 (49-127) | 34 (10-81) |
| (randomized) | n = 69 | n = 47 | n = 22 | |
| FAI ± G and/or ATRA | FA | 30 (23-40) | 44 (30-63) | 23 (15-35) |
| (randomized) | n = 248 | n = 89 | n = 159 | |
| FAI + G or ATRA | FA | 28 (18-39) | 36 (16-66) | 25 (15-35) |
| (not randomized) | n = 136 | n = 60 | n = 76 | |
| FA or FLAG | FA | 32 (27-46) | 51 (41-88) | 20 (10-32) |
| n = 216 | n = 97 | n = 119 | ||
| TA | TA | 38 (30-48) | 45 (25-67) | 38 (27-52) |
| n = 98 | n = 23 | n = 75 | ||
| CAT | TA | 45 (35-58) | 58 (46-97) | 30 (23-41) |
| n = 259 | n = 136 | n = 123 | ||
| Trial . | Group . | Median survival, wk (95% CI) . | ||
|---|---|---|---|---|
| Overall . | Age < 60 y . | Age ≥ 60 y . | ||
| IA | IA | 77 (56-132) | 169 (96 to —) | 47 (32-69) |
| n = 84 | n = 54 | n = 30 | ||
| IA + G-CSF (G) | IA | 86 (58-123) | 123 (86-182) | 36 (17-94) |
| n = 144 | n = 83 | n = 61 | ||
| IA + G + ATRA | IA | 83 (41 to —) | 81 (34 to —) | 83 (52 to —) |
| n = 25 | n = 20 | n = 5 | ||
| IA ± lisofylline | IA | 53 (44-88) | 61 (49-127) | 34 (10-81) |
| (randomized) | n = 69 | n = 47 | n = 22 | |
| FAI ± G and/or ATRA | FA | 30 (23-40) | 44 (30-63) | 23 (15-35) |
| (randomized) | n = 248 | n = 89 | n = 159 | |
| FAI + G or ATRA | FA | 28 (18-39) | 36 (16-66) | 25 (15-35) |
| (not randomized) | n = 136 | n = 60 | n = 76 | |
| FA or FLAG | FA | 32 (27-46) | 51 (41-88) | 20 (10-32) |
| n = 216 | n = 97 | n = 119 | ||
| TA | TA | 38 (30-48) | 45 (25-67) | 38 (27-52) |
| n = 98 | n = 23 | n = 75 | ||
| CAT | TA | 45 (35-58) | 58 (46-97) | 30 (23-41) |
| n = 259 | n = 136 | n = 123 | ||
CI, confidence interval; IA, idarubicin + ara-C; G-CSF, granulocyte colony-stimulating factor; ATRA, all-trans retinoic acid; FAI, fludarabine + ara-C + idarubicin; FA, fludarabine + ara-C; FLAG, FA + G-CSF; TA, topotecan + ara-C; CAT, cyclophosphamide + G-CSF.